Previous Article | Next Article ![]()
Journal of Virology, October 2000, p. 9742-9748, Vol. 74, No. 20
Cancer Research Center, Boston University
School of Medicine, Boston, Massachusetts,1 and
Departments of Pathology and Biochemistry and Molecular
Biology, University of Southern California School of Medicine, Los
Angeles, California2
Received 20 March 2000/Accepted 17 July 2000
We have previously reported that the long terminal repeat (LTR)
region of feline leukemia viruses (FeLVs) can enhance expression of
certain cellular genes such as the collagenase IV gene and MCP-1 in trans (S. K. Ghosh and D. V. Faller, J. Virol. 73:4931-4940, 1999). Genomic DNA of all healthy
feline species also contains LTR-like sequences that are related to
exogenous FeLV LTRs. In this study, we evaluated the cellular gene
transactivational potential of these endogenous FeLV LTR sequences.
Unlike their exogenous FeLV counterparts, neither nearly full-length
endogenous FeLV molecular clones (CFE-6 and CFE-16) nor their isolated
LTRs were able to activate collagenase IV gene or MCP-1
expression in transient transfection assays. We had also demonstrated
previously that production of an RNA transcript from exogenous FeLV
LTRs correlates with their transactivational activity. In the present
study, we demonstrate that the endogenous FeLV LTRs do not generate
LTR-specific RNA transcripts in the feline embryo fibroblast cell line
AH927. Furthermore, infection of AH927 cells by an exogenous FeLV
subgroup A virus did not induce production of such LTR-specific
transcripts from the endogenous proviral genomes, although the
LTR-specific transcripts from the exogenous virus were readily
detected. Finally, LTR-specific transcripts were not generated in
BALB/3T3 cells transiently transfected with isolated CFE-6 LTR, in
contrast to transfections with LTRs from exogenous viruses. Our data
thus suggest that the inability of endogenous FeLV LTRs in gene
transactivation is not due to cell line specificity or presence of any
upstream inhibitory cis-acting element. Endogenous,
nonleukemogenic FeLV LTRs, therefore, do not transactivate cellular
gene expression, and this property appears to be specific to exogenous,
leukemogenic FeLVs.
Feline leukemia virus (FeLV)
produces acute leukemia and lymphoma in domestic cats and can be
transmitted horizontally from animal to animal as an infectious
disease. FeLVs, like murine leukemia viruses (MuLVs), do not contain an
oncogene, and their precise molecular mechanism of tumorigenesis is not
fully understood. It is well established, however, that the U3 region
of the leukemia virus long terminal repeat (LTR), which contains
binding sites for various transcription factors, plays a key role in
their disease pathogenesis (6, 11, 22, 36). Because of
selective expression of different transcription factors in different
tissues, these enhancer elements can influence tissue tropism and
consequently disease specificity and pathogenic potential (18, 34,
41, 42). Duplication of the U3 enhancer region has been shown to be closely related to leukemogenic potential (24, 30). Other specific sequence motifs downstream of the enhancer sequence, or a
tandem triplication of 21 bp in the LTR, have also been implicated in
the pathogenesis of FeLV- and MuLV-mediated leukemogenesis (1, 19,
37, 40).
Previous studies from our laboratory have shown that the U3 region of
the LTR of Moloney murine leukemia virus (Mo-MuLV) can also activate
expression of specific cellular genes, such as the major
histocompatibility complex class I and T-cell receptor beta (TCR- All eukaryotic genomes, including the human genome, contain several
families of retrovirus-like elements (23, 26, 32, 38). These
elements, bordered by two LTRs, contain two or three basic retroviral
genes, gag and pol (and sometimes
env). These elements may have been introduced by infection
of germ line cells by exogenous retroviruses and subsequent vertical
transmission. The presence of these endogenous sequences may have
detrimental effects on the cell, such as expression of viral
transcripts and insertional activation or inactivation of important
host genes. Conversely, beneficial effects conferred by these
endogenous proviral sequences may include host resistance to exogenous
virus infection by receptor blockade. Sequence analysis of these
endogenous retroviruses indicates that they are frequently riddled with
a variety of mutations (4, 9). Genomic DNA from uninfected
cats possesses about 8 to 12 copies of endogenous FeLV-related
sequences per haploid genome (2, 5, 27-29). Although they
are not inducible as infectious virus particles, they can express
subgenomic transcripts in a tissue-specific manner. Molecular cloning
of these endogenous viral elements from specific-pathogen-free cats and
analysis of their nucleotide sequences demonstrated that they are
flanked by LTR sequences (34, 35). In this study, we
determined whether these endogenous FeLV LTRs can augment cellular gene
expression like their exogenous FeLV counterparts and if these LTRs can
generate LTR-specific RNA transcripts.
Since the normal feline genome contains endogenous FeLV-related
sequences, we asked whether these sequences also possess similar transactivational activity toward specific cellular genes. We tested
two endogenous FeLV proviral clones, CFE-6 and CFE-16, obtained from
pathogen-free feline placental DNA (35), for this purpose.
One of these two clones, CFE-6, possesses all of the viral structural
genes (gag, pol, and env) and LTRs
with sizes very similar to those of complete exogenous viruses. Clone
CFE-16, in contrast, has an approximately 4.0-kb deletion which
truncates both pol and env genes. Neither of
these two clones, however, generates any infectious virus particles
upon transfection (35). We tested these two clones for the
ability to transactivate the collagenase IV gene. BALB/3T3 cells were
cotransfected with these clones along with a reporter plasmid wherein
the chloramphenicol acetyltransferase (CAT) gene was placed under the
control of the collagenase IV gene promoter sequences from
0022-538X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Long Terminal Repeat Regions from Exogenous but Not
Endogenous Feline Leukemia Viruses Transactivate Cellular
Gene Expression
![]()
ABSTRACT
Top
Abstract
Text
References
![]()
TEXT
Top
Abstract
Text
References
)
genes, the collagenase IV gene (MMP-9), and MCP-1
(12-16, 21, 39). This activation takes place at the level
of transcription and is independent of physical location of the
effector (U3-LTR sequence) or the responsive genes and is thus a true
trans effect rather than due to positional or insertional
activation. Dysregulated expression of each of these cellular genes has
been documented in various malignancies. We have recently reported that
the U3-LTR region of FeLV subgroup A (FeLV-A) exhibits a similar
cellular gene transactivational activity (17). Furthermore,
we demonstrated that a specific RNA transcript is generated from the
U3-LTR region and that the transactivational activity is closely
related to the ability of the LTR to generate such a transcript
(7, 8, 17). Although we have not fully elucidated the
molecular pathways underlying the transactivation of cellular genes by
the LTR-specific transcript or the importance of this activation
property in leukemogenesis, our findings suggested that the cellular
gene activation property of the LTR could play an important role in
FeLV- or Mo-MuLV-mediated tumorigenesis.
517 to +62
(
517/+62 Coll-CAT). We have shown previously that the U3-LTR region
from both FeLV-A and Mo-MuLV can strongly activate this collagenase gene promoter (13, 17). To avoid interference from
endogenous FeLV sequences present in the genome of the transfected
cells, we did not use cells of feline origin in this assay. As shown in
Fig. 1, the CAT activity induced by the
endogenous FeLV clones CFE-6 and CFE-16 (1.5 and 1.8 times control,
respectively) was not significantly different from that generated by
the control backbone vector plasmid pTZ19U alone. In contrast, the
exogenous full-length FeLV-A clone p61E and its LTR clone p61E-LTR
activated reporter expression significantly, up to 4.5- and 12-fold,
respectively, as reported previously (17). These data thus
demonstrate that endogenous FeLV sequences do not possess
transactivational activity toward the
517/+62 collagenase gene
promoter in BALB/3T3 cells. In separate experiments, we found that
these two endogenous FeLVs, in contrast to their exogenous counterparts
(17), do not transactivate the MCP-1 or major
histocompatibility complex class I gene promoters either (data not
shown).

View larger version (50K):
[in a new window]
FIG. 1.
Transcriptional activation of a collagenase IV gene
promoter reporter by endogenous FeLV proviral clones. One microgram of
the
517/+62 Coll-CAT reporter plasmid was cotransfected with 10 µg
of clone CFE-6 or CFE-16 into BALB/3T3 cells by the DEAE-dextran
method. Exogenous full-length FeLV-A clone 61E (10 µg) and its LTR
subclone 61E-LTR (7.5 µg) were used as positive controls.
Cotransfection with 7.5 µg of backbone vector plasmid pTZ19U was used
to determine the constitutive basal expression of the collagenase IV
gene promoter reporter vector. Transfections with clones 61E, CFE-6,
and CFE-16 were done in duplicate. Efficiency of transfection was
monitored by cotransfection of 1 µg of an expression plasmid for
green fluorescent protein for each plate. Forty-eight hours after
transfection, cells were washed with phosphate-buffered saline and
assessed microscopically for green fluorescence under UV light to
normalize transfection efficiency. CAT assay was performed on the cell
lysates, and products were separated by thin-layer chromatography.
These experiments were repeated three times. The thin-layer
chromatogram of one representative experiment is shown. Autoradiographs
were photographed by AlphaImager 3.4, and quantitative analysis of the
percent conversion (fold activation) for each sample was done by
densitometric analysis of the image using the AlphaEase program (Alpha
Innotech). Ac-Cam, acetylated chloramphenicol; Cam, chloramphenicol.
We have shown in the case of exogenous FeLVs that the minimum LTR
sequences necessary for transactivational activity do not encode a
protein product. Instead, this LTR sequence generates a specific RNA
transcript, and as in the case of Mo-MuLV, this transcript appears to
be related to the transactivational activity of the LTR (8,
17). We therefore wished to determine if endogenous FeLVs can
generate an LTR-specific RNA transcript. We used a reverse transcriptase (RT)-PCR-based technique to detect any such transcripts. This technique is based on the fact that all regular retroviral transcripts are terminated at a polyadenylation site within the R
region of the 3' LTR. As such, reverse transcription with primers complementary to sequences downstream of this polyadenylation site and
subsequent PCR amplification with a primer binding in the U3 region
will detect only LTR-specific transcripts, not regular viral
transcripts (8, 17). To design specific primers for this
purpose, we first compared the FeLV-A (clone 61E) LTR sequences with
the two endogenous FeLV LTR sequences used in this study (Fig.
2). As previously noted (3),
sequences in the R and U5 regions of these LTRs are highly homologous
between exogenous and endogenous FeLVs but are quite divergent in the
U3 regions. We used a primer (P4) in the RT reaction with a sequence
complementary to the U5 region. When used together with a 5'-PCR primer
(P2) in these RT-PCRs, P4 will detect only LTR-specific transcripts from exogenous FeLV-A. In other RT reactions, we also used primer P3,
which is complementary to the R region. This primer can reverse transcribe both LTR-specific and regular viral transcripts. Because identical P3 and P4 primer binding sequences are present on LTRs from
both endogenous and exogenous FeLVs, these primers were also used in
the RT-PCRs to detect LTR-specific RNA transcripts generated by
endogenous FeLVs. As we had not yet determined the precise origin of
any putative LTR transcript from endogenous LTRs, we chose two
different 5'-PCR primers, P5 and P6. These primers were designed from
the sequence of an endogenous FeLV (CFE-6) LTR (positions
207 to
187 and
151 to
131, respectively) (Fig. 2). We isolated total
cellular RNA from uninfected feline embryo fibroblast cells (line
AH927) and performed RT-PCR to determine if endogenous-LTR-specific RNA
transcripts are generated. Total cellular RNA from these cells was
isolated by lysing actively growing AH927 cells in the presence of a
denaturing reagent (4 M guanidine thiocyanate) followed by phenol-chloroform extraction and isopropanol precipitation
(17). RNA samples were treated with RQ1 RNase-free DNase
(Promega Corporation) at a concentration of 0.1 U/µl at 37°C for 30 min. To demonstrate that AH927 cells indeed contain these endogenous
sequences, we used the same primer pairs to PCR amplify the LTRs from
the genomic DNA of these cells. At the same time, we also used
molecular clones of exogenous FeLV-A (p61E) and endogenous FeLV (CFE-6)
to test the specificity of these primers. As shown in Fig.
3A, primer pairs P5-P4 and P6-P4
amplified 331- and 274-bp fragments, respectively, both from AH927
genomic DNA and from a plasmid containing a molecular clone of CFE-6
(lanes 7 to 10). This demonstrates that AH927 cells contain endogenous
FeLV LTR sequences similar to CFE-6 in size and sequence. Neither the
P5-P4 nor P6-P4 pair, however, amplified any RNA transcripts in RT-PCR
using total RNA from uninfected AH927 cells (lanes 3 through 6). RNA
from exogenous FeLV-A 61E-infected AH927 cells was reverse transcribed
with primer P4 and PCR amplified with primer P2 (lanes 1 and 2). As
shown previously, a 350-bp amplified product was detected in this
sample (lane 2), but no product was generated when the RT enzyme was
omitted from the reaction mixture (lane 1).
|
|
Similar results were obtained when the other RT primer, P3 (which should detect both viral and LTR-specific transcripts), was used (Fig. 3B). Primer pairs P5-P3 and P6-P3 amplified 228- and 171-bp fragments, respectively, both from AH927 genomic DNA and from a plasmid containing the molecular clone CFE-6 (lanes 5 to 8). The failure to generate a PCR product in reactions using primer P5 or P6 and exogenous FeLV-A molecular clone p61E as the template (lanes 9 and 10) demonstrated the specificity of these two primers for endogenous FeLV LTR sequences. Occasionally we detected a faint band with the P4-P5 (Fig. 3A, lane 4) or P3-P5 (Fig. 3B, lane 2) primer pair, but bands were never detected using a more internal primer (P6) in any RT-PCR (Fig. 3A, lanes 6; Fig. 3B, lane 4). It is therefore highly unlikely that these occasional faint bands were generated from an endogenous LTR transcript. These data thus suggest that LTR transcripts are not made by endogenous FeLV sequences in AH927 cells and that there is negligible production of normal viral transcripts from them.
Although expression from endogenous FeLV elements has been reported in placenta, fetal lymphoid tissues, and some FeLV-negative lymphomas, their level of expression is low (5, 25, 28). In contrast, substantial levels of expression from endogenous FeLV sequences have been detected from certain FeLV-positive tumor cell lines, such as F422 and FL-74 (25). We therefore wished to determine whether infection of AH927 cells with exogenous FeLV could induce expression of the endogenous FeLV. We analyzed total RNA extracted from FeLV-A 61E-infected AH927 cells for the presence of endogenous FeLV LTR-specific RNA transcripts. The FeLV-infected cell line was generated by transfecting AH927 cells with exogenous FeLV-A 61E. After three passages, FeLV core protein antigen p27 production was detected with a Viracheck enzyme immunoassay kit (Synbiotics, Inc., San Diego, Calif.), confirming the infection. As shown in Fig. 3C and previously (17), primer pairs P3-P2 and P4-P2 amplified 247- and 350-bp exogenous FeLV-specific fragments, respectively (lanes 2 and 5), from this FeLV-A 61E-infected AH927 RNA. However, no endogenous FeLV LTR-specific fragment was amplified when the P3-P6 or P4-P6 primer pair was used (lanes 4 and 6). In control PCRs, primer pair P3-P2 amplified a 247-bp fragment from the exogenous FeLV-A plasmid clone 61E-LTR (lane 7), as well as a 269-bp fragment from the endogenous FeLV plasmid clone CFE6-LTR (lane 8). The P3-P6 primer pair amplified a 178-bp product from pCFE6-LTR (lane 11) but generated no p61E-LTR (lane 10). These results thus show that endogenous FeLV-specific LTR transcripts are not generated in AH927 cells, even when they are infected with exogenous FeLVs.
It has been reported previously that levels of expression from some
endogenous FeLVs may be determined by cis-acting elements present in the upstream cellular sequences (3). The two
endogenous FeLV clones that we used in our cellular gene
transactivational activity studies (CFE-6 and CFE-16) contain
cell-derived sequences adjacent to the LTRs. It was formally possible
that the inability of these clones to cause gene transactivation was
due to the presence of those cell-derived flanking sequences. We
therefore isolated the LTRs from the endogenous FeLVs and assessed
their gene transactivational activity potential. We first identified
the minimum region of the exogenous FeLV-A LTR that was sufficient to
confer transactivational activity by generating eight 5'- and/or 3'-end
deletion constructs from the exogenous FeLV LTR subclone p61E-LTR.
Various regions of the LTR were amplified by PCR using specific primer
pairs and subcloned into the pGEM3Z vector (Promega). The nucleotide
sequences of these clones were all verified before they were used in
any experiment. The transactivational activities of these smaller LTR
constructs were then analyzed in cotransfection experiments with the
517/+62 Coll-CAT reporter plasmid in BALB/3T3 cells. One of these
clones, 61E-H, which includes FeLV-A LTR sequence from
248 to
39,
was found to be the smallest region sufficient for wild-type-level
collagenase gene promoter transactivation (Fig.
4A and B) (detailed analysis of these
clones will be reported elsewhere). Primers M5 and M7 (Table
1) were used to generate clone 61E-H.
|
|
Once we had identified the smallest region of exogenous FeLV LTR
necessary for gene transactivation, we constructed analogous, similarly
sized LTR clones from the full-length endogenous FeLV clone CFE-6. A
362-bp endogenous FeLV CFE-6 LTR subclone (CFE6-LTR) was constructed by
PCR, using primer pair P7-P8 (Fig. 2 and 4A). This clone contains the
same LTR region as the exogenous FeLV clone 61E-LTR. A second, smaller
227-bp endogenous LTR subclone containing the LTR region similar to
clone 61E-H (CFE6-3) was also generated by PCR, using primer pair
M5c-M7c (Fig. 2 and 4A). Following verification of their nucleotide
sequences, clones CFE6-LTR and CFE6-3 were tested for the ability to
transactivate the collagenase gene promoter in cotransfection assays.
Neither of these clones could transactivate the
517/+62 Coll-CAT
reporter in cotransfection assays (Fig. 4B). These results suggest that
the inability of the endogenous FeLV LTRs to transactivate the
collagenase gene promoter in our experiments is not due the presence of
adjacent cellular sequences.
Since we have reported previously that feline and murine LTRs with transactivational activities also generate LTR-specific RNA transcripts and that these transcripts are required for transactivational activity (8, 17), we next determined if endogenous FeLV LTRs generate such a transcript. We transfected the endogenous FeLV LTR clones CFE6-LTR and CFE6-3, as well as the exogenous FeLV-A LTR clones 61E-LTR and 61E-H, into BALB/3T3 cells. Forty-eight hours later, RNA was isolated from these transfected cells by the guanidine isothiocyanate extraction followed by DNase treatment. The presence of LTR-specific RNA transcripts was ascertained by RT-PCR using primers specific for the individual clones tested. The RT primers used for the smaller LTR clones 61E-H and CFE6-3 were P19 and P20, respectively (Table 1 and Fig. 2); for the other two clones (61E-LTR and CFE6-LTR), the P3 RT primer was used. In PCRs, P2 and P5 were used as 5' primers for exogenous and endogenous clones, respectively. As shown in Fig. 4C, LTR-specific transcripts were detected from both of the LTRs of exogenous FeLV origin (247 bp for 61E-LTR and 170 bp for 61E-H). However, no amplified products of the appropriate size were generated by either of the endogenous FeLV LTR clones (228 bp for CFE6-LTR and 141 bp for CFE6-3). RT-PCR analysis of an RNA preparation from FeLV-A 61E-infected AH927 cells with primers P4 and P2 generated a 350-bp amplified product, as shown previously (17). These data thus demonstrate that endogenous FeLV LTRs do not produce RNA transcripts and further suggest a relationship between generation of LTR-specific RNA transcripts and gene transactivational activity by the FeLV LTR.
This study investigated the ability of endogenous FeLV LTRs to activate cellular gene expression. The LTRs of leukemia viruses play a central role in disease pathogenesis. They regulate transcription from the viral genome through the enhancer activity of the U3 region, enhancer multiplication, and the stem-loop structure in the R region (6, 10, 18, 33, 36). Additionally, we have hypothesized that the cellular gene transactivational activity of leukemia virus LTRs could also play an important role in leukemogenesis (13-15, 17). We report here that although exogenous FeLV-A LTRs could transactivate the collagenase IV gene and MCP-1 promoters, two nearly full-length endogenous FeLV clones and their isolated LTRs did not possess similar activity. The U3-LTR sequences from endogenous FeLVs differ substantially from the analogous region in the exogenous FeLV LTRs (Fig. 2). Although endogenous FeLV LTRs can function as enhancers in transient reporter assays (3), their inability to activate cellular gene expression in trans is likely the result of this sequence divergence. In parallel pilot experiments studying murine retroviruses, we have found that the LTRs of nonleukemogenic ecotropic MuLVs (gift from Arifa Khan) (20) also fail to demonstrate transactivational activity of cellular genes, in contrast to the strong transactivational activity of LTRs from exogenous, leukemogenic MuLVs. As observed with the FeLVs, the nucleotide sequences of these endogenous viral LTRs differed in the U3 region from the LTRs of leukemogenic MuLV.
Alteration in the LTR enhancer sequence and/or the presence of negative cis-acting control elements in adjacent cellular sequences have been implicated in the repression of transcription from endogenous FeLV sequences (3). In our transient transfection assays, we used a nearly full-length FeLV clone (CFE-6), as well as an endogenous FeLV clone containing a large deletion (CFE-16). Previous studies using transient transfection reported that transcription from CFE-16, but not from CFE-6, could be demonstrated (3). In the case of CFE-6, the lack of expression was shown to be due the presence of inhibitory cellular sequences upstream of the LTR. In our assays, however, neither of these endogenous viruses could transactivate the collagenase gene promoter (Fig. 1). To eliminate the possibility that adjacent cellular sequences included in the proviral clones might have influenced their activity, we studied isolated regions of the LTR alone. The smaller endogenous FeLV LTR constructs, CFE6-LTR and CFE6-3, used in our study represent equivalent regions to a region of the exogenous FeLV LTR that is known to have transactivational activity. Since CFE6-LTR and CFE6-3 clones had no cellular sequences associated with them and still failed to demonstrate transactivational activity, the possibility of a cis-acting negative regulatory effect by adjacent cellular sequences was ruled out.
Although we have demonstrated that both Mo-MuLV and FeLV LTRs can transactivate cellular gene expression, the mechanism underlying this activity is not completely understood. We have previously demonstrated that these viruses produce LTR-specific RNA transcripts and that the generation of these transcripts is necessary for transactivational activity (7, 8, 17). In the present study, we were unable to detect any endogenous LTR-specific transcripts in the feline embryo fibroblast cell line AH927. Genomic DNA from these cells, however, did contain FeLV sequences similar to the endogenous feline proviral clone CFE-6 (Fig. 3). No regular viral transcripts were detected in AH927 cells either, suggesting that transcription from these naturally occurring endogenous FeLV sequences does not normally take place in AH927 cells. This finding is consistent with a recent report that endogenous FeLV-specific expression was not detectable in this cell line (25). In contrast, the same investigators found that certain FeLV-positive tumor cell lines, such as F422 and FL-74, did express their endogenous FeLV elements. Infection of AH927 cells with FeLV-A, however, did not induce expression from the endogenous FeLV sequences in our studies. We do not yet know whether the lack of inducible expression of the endogenous FeLV elements in AH927 cells is specific for this cell line. It may be informative to examine endogenous virus LTR-mediated gene transactivation in other feline cell lines, such as A3201 and FL74, where endogenous FeLV expression can reportedly be induced (25).
Earlier studies have shown that transient transfection of certain endogenous FeLV clones into murine fibroblasts such as NIH 3T3 cells could result in transcription of viral genes (3, 35). We therefore attempted to demonstrate LTR-specific RNA transcript production by endogenous FeLVs in murine fibroblasts (BALB/3T3), to address the potential concern that failure to detect such transcripts in AH927 cells was due to cell line specificity. Production of LTR-specific RNA transcripts by endogenous viral LTRs did not occur in BALB/3T3 cells, whereas LTRs from exogenous FeLVs did generate such transcripts in this cell line. Consistent with our hypothesis that the LTR transcript mediates transactivation of cellular genes, LTR clones from endogenous FeLVs exhibited no transactivational activity when they were transfected in BALB/3T3 cells, in contrast to the significant transactivational activity exhibited by LTRs from exogenous FeLV clones. Identical results were obtained when these experiments were repeated in NIH 3T3 cells (data not shown). Together, our findings suggest that the failure of the endogenous FeLV LTRs to induce gene transactivation in our study is not cell line specific.
Although we have observed a consistent direct relationship between LTR-specific RNA transcript production and cellular gene transactivation in our experiments, we have not yet demonstrated a causal relationship between these activities for the FeLVs. Construction of chimeric exogenous-endogenous FeLV LTRs is under way to more precisely define LTR sequence requirements for the transactivation function and transcript production. The data from such experiments will be critical in designing transactivation-deficient mutant proviruses for evaluation of the biological relevance of LTR-mediated host cell gene activation in tumorigenesis.
| |
ACKNOWLEDGMENTS |
|---|
We thank Julie Overbaugh, Brian Seed, and Peter Angel for their generous gifts of plasmids used in this study. Full-length FeLV-A clone 61E was obtained through the NIH AIDS Research and Reference Reagent Program.
This work was supported by National Institutes of Health grants P60AR20613 and CA50459 (D.V.F.), by a New Investigator research grant from the Massachusetts Division of the American Cancer Society (S.K.G.), and by Institutional Research Grant IRG7200124 from the American Cancer Society (S.K.G.).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Cancer Research Center, Boston University School of Medicine, 80 E. Concord St., L911, Boston, MA 02118. Phone: (617) 638-5615. Fax: (617) 638-4176. E-mail: sajal{at}bu.edu.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Athas, G. B., P. Lobelle-Rich, and L. S. Levy. 1995. Function of a unique sequence motif in the long terminal repeat of feline leukemia virus isolated from an unusual set of naturally occurring tumors. J. Virol. 69:3324-3332[Abstract]. |
| 2. |
Benveniste, R. E.,
C. J. Sherr, and G. J. Todaro.
1975.
Evolution of type C viral genes: origin of feline leukemia virus.
Science
190:886-888 |
| 3. |
Berry, B. T.,
A. K. Ghosh,
D. V. Kumar,
D. A. Spodick, and P. Roy-Burman.
1988.
Structure and function of endogenous feline leukemia virus long terminal repeats and adjoining regions.
J. Virol.
62:3631-3641 |
| 4. | Boeke, J. D., and J. P. Stoye. 1997. Retrotransposons, endogenous retroviruses, and the evolution of retroelements, p. 343-436. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. |
| 5. | Busch, M. P., B. G. Devi, L. H. Soe, B. Perbal, M. A. Baluda, and P. Roy-Burman. 1983. Characterization of the expression of cellular retrovirus genes and oncogenes in feline cells. Hematol. Oncol. 1:61-75[Medline]. |
| 6. |
Chatis, P. A.,
C. A. Holland,
J. E. Silver,
T. N. Frederickson,
N. Hopkins, and J. W. Hartley.
1984.
A 3' end fragment encompassing the transcriptional enhancers of nondefective Friend virus confers erythroleukemogenicity on Moloney leukemia virus.
J. Virol.
52:248-254 |
| 7. |
Choi, S. Y., and D. V. Faller.
1994.
The long terminal repeats of a murine retrovirus encode a trans-activator for cellular genes.
J. Biol. Chem.
269:19691-19694 |
| 8. | Choi, S. Y., and D. V. Faller. 1995. A transcript from the long terminal repeats of a murine retrovirus associated with trans activation of cellular genes. J. Virol. 69:7054-7060[Abstract]. |
| 9. | Coffin, J. M. 1996. Retroviridae: the viruses and their replication, p. 763-843. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fundamental virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 10. |
Cupelli, L.,
S. A. Okenquist,
A. Trubetskoy, and J. Lenz.
1998.
The secondary structure of the R region of a murine leukemia virus is important for stimulation of long terminal repeat-driven gene expression.
J. Virol.
72:7807-7814 |
| 11. |
DesGroseillers, L., and P. Jolicoeur.
1984.
The tandem direct repeats within the long terminal repeat of murine leukemia viruses are the primary determinant of their leukemogenic potential.
J. Virol.
52:945-952 |
| 12. | Faller, D. V. 1995. Modulation of MHC antigen expression by retroviruses, p. 150-191. In G. E. Blair, D. J. Maudsley, and C. R. Pringle (ed.), MHC antigen expression and disease. Cambridge University Press, Cambridge, England. |
| 13. | Faller, D. V., H. Weng, and S. Y. Choi. 1997. Activation of collagenase IV gene expression and enzymatic activity by the Moloney murine leukemia virus long terminal repeat. Virology 227:331-342[CrossRef][Medline]. |
| 14. | Faller, D. V., H. Weng, D. T. Graves, and S. Y. Choi. 1997. Moloney murine leukemia virus long terminal repeat activates monocyte chemotactic protein-1 protein expression and chemotactic activity. J. Cell. Physiol. 172:240-252[CrossRef][Medline]. |
| 15. | Faller, D. V., L. D. Wilson, and D. C. Flyer. 1988. Mechanism of induction of class I major histocompatibility antigen expression by murine leukemia virus. J. Cell. Biochem. 36:297-309[CrossRef][Medline]. |
| 16. | Flyer, D. C., S. J. Burakoff, and D. V. Faller. 1985. Retrovirus-induced changes in major histocompatibility complex antigen expression influence susceptibility to lysis by cytotoxic T lymphocytes. J. Immunol. 135:2287-2292[Abstract]. |
| 17. |
Ghosh, S. K., and D. V. Faller.
1999.
Feline leukemia virus long terminal repeat activates collagenase IV expression through AP-1.
J. Virol.
73:4931-4940 |
| 18. |
Golemis, E.,
Y. Li,
T. N. Fredrickson,
J. W. Hartley, and N. Hopkins.
1989.
Distinct segments within the enhancer region collaborate to specify the type of leukemia induced by nondefective Friend and Moloney viruses.
J. Virol.
63:328-337 |
| 19. |
Hanecak, R.,
P. K. Pattengale, and H. Fan.
1991.
Deletion of a GC-rich region flanking the enhancer element within the long terminal repeat sequences alters the disease specificity of Moloney murine leukemia virus.
J. Virol.
65:5357-5363 |
| 20. |
Khan, A. S.,
W. P. Rowe, and M. A. Martin.
1982.
Cloning of endogenous murine leukemia virus-related sequences from chromosomal DNA of BALB/c and AKR/J mice: identification of an env progenitor of AKR-247 mink cell focus-forming proviral DNA.
J. Virol.
44:625-636 |
| 21. | Koka, P., K. van de Mark, and D. V. Faller. 1991. Trans-activation of genes encoding activation-associated human T lymphocyte surface proteins by murine retroviral sequences. J. Immunol. 146:2417-2425[Abstract]. |
| 22. | Lenz, J., D. Celander, R. L. Crowther, R. Patarca, D. W. Perkins, and W. A. Haseltine. 1984. Determination of the leukemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308:467-470[CrossRef][Medline]. |
| 23. |
Lower, R.,
J. Lower, and R. Kurth.
1996.
The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences.
Proc. Natl. Acad. Sci. USA
93:5177-5184 |
| 24. | Matsumoto, Y., Y. Momoi, T. Watari, R. Goitsuka, H. Tsujimoto, and A. Hasegawa. 1992. Detection of enhancer repeats in the long terminal repeats of feline leukemia viruses from cats with spontaneous neoplastic and nonneoplastic diseases. Virology 189:745-749[CrossRef][Medline]. |
| 25. |
McDougall, A. S.,
A. Terry,
T. Tzavaras,
C. Cheney,
J. Rojko, and J. C. Neil.
1994.
Defective endogenous proviruses are expressed in feline lymphoid cells: evidence for a role in natural resistance to subgroup B feline leukemia viruses.
J. Virol.
68:2151-2160 |
| 26. |
Medstrand, P., and D. L. Mager.
1998.
Human-specific integrations of the HERV-K endogenous retrovirus family.
J. Virol.
72:9782-9787 |
| 27. | Niman, H. L., M. Akhavi, M. B. Gardner, J. R. Stephenson, and P. Roy-Burman. 1980. Differential expression of two distinct endogenous retrovirus genomes in developing tissues of the domestic cat. J. Natl. Cancer Inst. 64:587-594. |
| 28. | Niman, H. L., J. R. Stephenson, M. B. Gardner, and P. Roy-Burman. 1977. RD-114 and feline leukaemia virus genome expression in natural lymphomas of domestic cats. Nature 266:357-360[CrossRef][Medline]. |
| 29. | Overbaugh, J., N. Riedel, E. A. Hoover, and J. I. Mullins. 1988. Transduction of endogenous envelope genes by feline leukaemia virus in vitro. Nature 332:731-734[CrossRef][Medline]. |
| 30. | Rohn, J. L., and J. Overbaugh. 1995. In vivo selection of long terminal repeat alterations in feline leukemia virus-induced thymic lymphomas. Virology 206:661-665[CrossRef][Medline]. |
| 31. |
Shaw, G. M.,
B. H. Hahn,
S. K. Arya,
J. E. Groopman,
R. C. Gallo, and F. Wong-Staal.
1984.
Molecular characterization of human T-cell leukemia (lymphotropic) virus type III in the acquired immunodeficiency syndrome.
Science
226:1165-1171 |
| 32. | Shih, A., E. E. Coutavas, and M. G. Rush. 1991. Evolutionary implications of primate endogenous retroviruses. Virology 182:495-502[CrossRef][Medline]. |
| 33. |
Short, M. K.,
S. A. Okenquist, and J. Lenz.
1987.
Correlation of leukemogenic potential of murine retroviruses with transcriptional tissue preference of the viral long terminal repeats.
J. Virol.
61:1067-1072 |
| 34. |
Soe, L. H.,
B. G. Devi,
J. I. Mullins, and P. Roy-Burman.
1983.
Molecular cloning and characterization of endogenous feline leukemia virus sequences from a cat genomic library.
J. Virol.
46:829-840 |
| 35. |
Soe, L. H.,
R. W. Shimizu,
J. R. Landolph, and P. Roy-Burman.
1985.
Molecular analysis of several classes of endogenous feline leukemia virus elements.
J. Virol.
56:701-710 |
| 36. |
Speck, N. A.,
B. Renjifo,
E. Golemix,
T. Fredrickson,
J. Hartley, and N. Hopkins.
1990.
Mutation of the core or adjacent LVb elements of the Moloney murine leukemia virus enhancer alters disease specificity.
Genes Dev.
4:233-242 |
| 37. |
Starkey, C. R.,
P. A. Lobelle-Rich,
S. Granger,
B. K. Brightman,
H. Fan, and L. S. Levy.
1998.
Tumorigenic potential of a recombinant retrovirus containing sequences from Moloney murine leukemia virus and feline leukemia virus.
J. Virol.
72:1078-1084 |
| 38. | Wilkinson, D. A., D. L. Mager, and J.-A. C. Leong. 1994. Endogenous human retroviruses, p. 465-535. In J. Levy (ed.), The Retroviridae, vol. 3. Plenum Press, New York, N.Y. |
| 39. |
Wilson, L. D.,
D. C. Flyer, and D. V. Faller.
1987.
Murine retroviruses control class I major histocompatibility antigen gene expression via a trans effect at the transcriptional level.
Mol. Cell. Biol.
7:2406-2415 |
| 40. |
Yoshimura, F. K.,
T. Wang, and M. Cankovic.
1999.
Sequences between the enhancer and promoter in the long terminal repeat affect murine leukemia virus pathogenicity and replication in the thymus.
J. Virol.
73:4890-4898 |
| 41. | Zaiman, A. L., A. F. Lewis, B. E. Crute, N. A. Speck, and J. Lenz. 1995. Transcriptional activity of core binding factor alpha (AML1) and beta subunits on murine leukemia virus enhancer cores. J. Virol. 69:2898-2906[Abstract]. |
| 42. |
Zaiman, A. L.,
A. Nieves, and J. Lenz.
1998.
CBF, Myb, and Ets binding sites are important for activity of the core I element of the murine retrovirus SL3-3 in T lymphocytes.
J. Virol.
72:3129-3137 |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»